Douglas Evan  Godshall net worth and biography

Douglas Godshall Biography and Net Worth

Doug joined Shockwave as Chief Executive Officer in May 2017 to lead the company into US commercialization and international expansion.   This followed his most recent tenure as the CEO and a Director of HeartWare, a leader in the LVAD market. He managed the organization from a pre-commercial phase to over $250M in sales until it was acquired by Medtronic in August of 2016 for $1.1B.

Prior to HeartWare, Doug held other executive and leadership positions at Boston Scientific, including President of the Vascular Surgery Division, member of Boston Sci’s Operating Committee and Vice President of Business Development where he was responsible for more than 70 transactions, many in the arena of coronary and peripheral interventions.

Doug earned an MBA from Northeastern University and a BA in Economics from Lafayette College.

What is Douglas Evan Godshall's net worth?

The estimated net worth of Douglas Evan Godshall is at least $53.00 million as of February 15th, 2024. Mr. Godshall owns 162,762 shares of Shockwave Medical stock worth more than $53,000,190 as of March 28th. This net worth estimate does not reflect any other assets that Mr. Godshall may own. Additionally, Mr. Godshall receives an annual salary of $1,570,000.00 as CEO at Shockwave Medical. Learn More about Douglas Evan Godshall's net worth.

How old is Douglas Evan Godshall?

Mr. Godshall is currently 59 years old. There are 5 older executives and no younger executives at Shockwave Medical. Learn More on Douglas Evan Godshall's age.

What is Douglas Evan Godshall's salary?

As the CEO of Shockwave Medical, Inc., Mr. Godshall earns $1,570,000.00 per year. Learn More on Douglas Evan Godshall's salary.

How do I contact Douglas Evan Godshall?

The corporate mailing address for Mr. Godshall and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Douglas Evan Godshall's contact information.

Has Douglas Evan Godshall been buying or selling shares of Shockwave Medical?

During the past quarter, Douglas Evan Godshall has sold $6,492,000.00 in Shockwave Medical stock. Most recently, Douglas Evan Godshall sold 10,000 shares of the business's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $231.56, for a transaction totalling $2,315,600.00. Following the completion of the sale, the chief executive officer now directly owns 162,762 shares of the company's stock, valued at $37,689,168.72. Learn More on Douglas Evan Godshall's trading history.

Who are Shockwave Medical's active insiders?

Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.

Are insiders buying or selling shares of Shockwave Medical?

In the last year, insiders at the sold shares 47 times. They sold a total of 221,744 shares worth more than $52,184,011.04. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.

Information on this page was last updated on 3/26/2024.

Douglas Evan Godshall Insider Trading History at Shockwave Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2024Sell10,000$231.56$2,315,600.00162,762View SEC Filing Icon  
1/16/2024Sell10,000$217.59$2,175,900.00141,057View SEC Filing Icon  
1/5/2024Sell10,000$200.05$2,000,500.00141,057View SEC Filing Icon  
12/15/2023Sell5,000$187.80$939,000.00141,057View SEC Filing Icon  
11/15/2023Sell5,000$174.08$870,400.00136,057View SEC Filing Icon  
10/16/2023Sell10,000$200.78$2,007,800.00141,649View SEC Filing Icon  
9/15/2023Sell10,000$212.86$2,128,600.00141,649View SEC Filing Icon  
8/24/2023Sell10,000$214.62$2,146,200.00141,649View SEC Filing Icon  
2/21/2023Sell30,000$187.84$5,635,200.00114,741View SEC Filing Icon  
11/14/2022Sell30,000$240.81$7,224,300.0082,926View SEC Filing Icon  
8/11/2022Sell30,000$280.60$8,418,000.00112,926View SEC Filing Icon  
6/6/2022Sell7,400$177.32$1,312,168.00142,926View SEC Filing Icon  
5/27/2022Sell2,600$175.06$455,156.00142,926View SEC Filing Icon  
5/13/2022Sell5,000$150.00$750,000.00142,926View SEC Filing Icon  
5/11/2022Sell15,000$140.87$2,113,050.00142,926View SEC Filing Icon  
11/18/2021Sell45,000$207.28$9,327,600.00View SEC Filing Icon  
8/18/2021Sell45,000$188.08$8,463,600.00181,856View SEC Filing Icon  
5/18/2021Sell45,000$159.36$7,171,200.00181,856View SEC Filing Icon  
2/18/2021Sell45,000$121.96$5,488,200.00193,359View SEC Filing Icon  
11/17/2020Sell132,145$94.98$12,551,132.10230,083View SEC Filing Icon  
8/27/2020Sell849$60.00$50,940.0099,208View SEC Filing Icon  
8/24/2020Sell9,359$60.00$561,540.00107,718View SEC Filing Icon  
8/21/2020Sell16,750$60.02$1,005,335.00125,635View SEC Filing Icon  
8/4/2020Sell19,357$50.01$968,043.57109,002View SEC Filing Icon  
2/18/2020Sell30,000$43.23$1,296,900.0046,000View SEC Filing Icon  
11/21/2019Sell30,000$37.42$1,122,600.0046,000View SEC Filing Icon  
See Full Table

Douglas Evan Godshall Buying and Selling Activity at Shockwave Medical

This chart shows Douglas Evan Godshall's buying and selling at Shockwave Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Shockwave Medical Company Overview

Shockwave Medical logo
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $325.63
Low: $322.61
High: $331.58

50 Day Range

MA: $254.81
Low: $217.19
High: $325.63

2 Week Range

Now: $325.63
Low: $157.00
High: $331.58

Volume

814,172 shs

Average Volume

599,305 shs

Market Capitalization

$12.18 billion

P/E Ratio

84.14

Dividend Yield

N/A

Beta

0.9